Ashwagandha: what the research measures

Withania somnifera is the most-studied plant in the adaptogen category. What the trials actually measured, the extracts and doses they used, and why that doesn't transfer to a teacup.

By PGP Iyer · May 28, 2026 · 1 min read

Ashwagandha (Withania somnifera) is an Ayurvedic herb placed in the “adaptogen” category — a traditional grouping, not a regulatory or pharmacological one. It is the most-studied plant in that category, which is worth separating from the question of what the studies found.

What do the trials actually measure?

Read the methods rather than the abstracts and a pattern emerges: these are short trials, typically 6–8 weeks, using standardised root extracts at fixed doses, and their endpoints are self-reported questionnaire scores — perceived-stress scales, sleep-quality indices — sometimes alongside serum cortisol. Those are the measurements. What they describe is a body of research, not a result you should expect.

Why the extract matters more than the plant

Nearly every trial uses a standardised, concentrated root extract at a specific dose, characterised by its withanolide content. That is a different material from powdered root, and different again from anything steeped in water. Results attach to the material that was tested, and they do not travel to a product simply because it names the same plant.

Read the limits honestly

The literature is short-duration, heavily reliant on self-report, and much of it is industry-funded — limitations the reviews themselves raise. Ashwagandha is generally well tolerated over the short term, but it is not recommended in pregnancy and can interact with thyroid, sedative and immune-affecting medications. If any of those apply, speak to a clinician.